Clinical Trial Update: CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study of temsirolimus (CCI-779) in relapsed or refractory chronic lymphocytic leukemia has been terminated. The study also involved patients with diffus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 2 | Status: TERMINATED